Radius Health, Inc. (NASDAQ:RDUS) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -3.43% to 55.74 with about 1.95 Million shares have changed hands in this session. Radius Health (RDUS) reported that positive results from the Phase 3 ACTIVE trial were published in the Journal of the American Medical Association. This landmark trial enrolled 2,463 patients to evaluate the safety and efficacy of examinational drug abaloparatide for the treatment of postmenopausal women with osteoporosis. The ACTIVE results showed that patients treated with daily abaloparatide for 18 months had a importantly greater reduction in the incidence of new vertebral fractures (p < 0.001) and nonvertebral fractures (p = 0.049) compared to placebo. The stock is going forward its fifty-two week low with 125.21% and lagging behind from its 52-week high price with -27.70%.
The positive performance for the quarter recorded as 68.55% and for the year was -23.13%, while the YTD performance remained at -9.42%. RDUS has Average True Range for 14 days of 3.48.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) [Trend Analysis] retains strong position in active trade, as shares scoring 7.89% to $3.42 in a active trade session, while looking at the shares volume, about 1.75 Million shares have changed hands in this session. Anthera Pharmaceuticals, Inc. (ANTH) reported that appointment of William Shanahan, M.D., J.D. as Chief Medical Officer. In his role as Chief Medical Officer, Dr. Shanahan will bring his experience as a Rheumatologist and in drug development to lead the blisibimod lupus program and Sollpura program, with both programs predictable to report out topline data in the fourth quarter of this year.
He will also have accountability for the development of additional indications for blisibimod in diseases such as IgA nephropathy and cystic fibrosis and for Sollpura in celiac disease and other diseases. In addition, he will bring extensive experience with FDA and European filings to work closely with our regulatory team in preparing the Biologics License Applications (BLA) for both Sollpura and blisibimod. The firm has institutional ownership of 56.10%, while insider ownership included 12.46%. ANTH attains analyst recommendation of 1.60 with week’s performance of 11.04%. Investors looking additional ahead will note that the Price to next year’s EPS is 0.70%.
Shares of MeetMe, Inc. (NASDAQ:MEET) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -18.37% to close at $5.02. MeetMe, Inc. (MEET) reiterated that its financial guidance for the third quarter and full year of 2016 in response to recent volatility in the Firm’s share price and in anticipation of upcoming investor meetings. Income for the year is predictable to be in the range of $66.0 million to $68.0 million, representing growth of among 16% and 20% year over year.
Adjusted EBITDA for the year is predictable to be in the range of $25.0 million to $27.0 million, representing growth of among 24% to 33% year over year. Consolidated Full Year 2016 Guidance. (pending closing of Skout, Inc. acquisition, predictable in early October 2016) Income for the year is predictable to be in the range of $73.5 million to $75.5 million, which would include three months of income contribution from Skout. Adjusted EBITDA for the year is predictable to be in the range of $28.0 million to $30.0 million, which would include three months of adjusted EBITDA contribution from Skout. Moving forward to saw long-term intention, MEET; experts calculate Return on Investment of 6.90%. The stock is going forward its fifty-two week low with 241.50% and lagging behind from its 52-week high price with -38.10%. MEET last month stock price volatility remained 7.90%.